Analysts Set Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Target Price at $187.71

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) have earned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $187.71.

Several research analysts recently issued reports on the company. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Piper Sandler reaffirmed an “overweight” rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, March 5th. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. Finally, Truist Financial upped their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a research note on Thursday, March 6th.

Jazz Pharmaceuticals Stock Down 1.3 %

Shares of NASDAQ:JAZZ opened at $138.76 on Wednesday. The stock has a market cap of $8.43 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 1.04 and a beta of 0.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals has a 12-month low of $99.06 and a 12-month high of $148.06. The business’s 50 day moving average is $131.41 and its 200 day moving average is $121.61.

Insider Transactions at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the completion of the transaction, the chief executive officer now owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the transaction, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at $966,323.72. The trade was a 13.98 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 28,736 shares of company stock worth $4,022,825. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Bessemer Group Inc. raised its holdings in shares of Jazz Pharmaceuticals by 0.3% during the 4th quarter. Bessemer Group Inc. now owns 26,932 shares of the specialty pharmaceutical company’s stock valued at $3,317,000 after buying an additional 92 shares in the last quarter. CIBC Asset Management Inc raised its holdings in shares of Jazz Pharmaceuticals by 5.2% during the 4th quarter. CIBC Asset Management Inc now owns 1,972 shares of the specialty pharmaceutical company’s stock valued at $243,000 after buying an additional 97 shares in the last quarter. Synovus Financial Corp raised its holdings in shares of Jazz Pharmaceuticals by 0.5% during the 4th quarter. Synovus Financial Corp now owns 19,206 shares of the specialty pharmaceutical company’s stock valued at $2,365,000 after buying an additional 100 shares in the last quarter. Quarry LP raised its holdings in shares of Jazz Pharmaceuticals by 6.3% during the 4th quarter. Quarry LP now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $209,000 after buying an additional 100 shares in the last quarter. Finally, Quadrant Capital Group LLC raised its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.